Literature DB >> 20978940

Marked geographic aggregation of acute intermittent porphyria families carrying mutation Q180X in Venezuelan populations, with description of further mutations.

Irene Paradisi1, Sergio Arias.   

Abstract

Acute intermittent porphyria (AIP) caused by mutations in the hydroxymethylbilane synthase gene (HMBS), has been reported in almost all human populations, with varying frequencies. A founder effect for a few specific mutations in geographic regions where prevalence is high (Sweden, The Netherlands, Switzerland) has been established through haplotype analyses, while some other mutations (R26H, R26C) have been repeatedly reported in many populations with different genetic backgrounds. Epidemiological, biochemical and molecular data on AIP in Venezuela were gathered during the last two decades; 24 independent families with AIP were ascertained, based on a deficient HMBS activity and increased porphobilinogen (PBG) urinary excretion. Molecular analyses of coding and splicing regions were performed in 23 families, to establish disease-causing changes, and haplotype analyses were used to assess ancestral kinships between them. Changes were detected in 16 out of 23 families, 9 of them being different: R26H, R26C, c.87+5G>A, c.267-54_61delgaaggggt, R116W, Q180X, c.825+1G>A, c.913-1delG, and 3' UTR *277G>A. Seven mutations were found, each one in a single family; one mutation was present in two unrelated families, whereas mutation Q180X was shared by 7 independent kindreds, all of which had the same haplotype (-);T;A;T;G;T;A;G (3167delG; 3530T>C; 3581A>G; 3982T>C; 6479G>T; 7052T>C; 7064A>C; 7779G>A). Six out of seven different Q180X carrier families came from the same geographic focus (Santa Lucía, Miranda State). Dense geographic aggregation with one identical haplotype strongly suggests a remote founder phenomenon for these Venezuelan AIP families, carrying an unreported but most frequent mutation.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20978940     DOI: 10.1007/s10545-010-9228-x

Source DB:  PubMed          Journal:  J Inherit Metab Dis        ISSN: 0141-8955            Impact factor:   4.982


  38 in total

1.  Comparison of complementary and genomic DNA sequencing for the detection of mutations in the HMBS gene in British patients with acute intermittent porphyria: identification of 25 novel mutations.

Authors:  S D Whatley; J R Woolf; G H Elder
Journal:  Hum Genet       Date:  1999-06       Impact factor: 4.132

2.  Molecular epidemiology and diagnosis of PBG deaminase gene defects in acute intermittent porphyria.

Authors:  H Puy; J C Deybach; J Lamoril; A M Robreau; V Da Silva; L Gouya; B Grandchamp; Y Nordmann
Journal:  Am J Hum Genet       Date:  1997-06       Impact factor: 11.025

3.  A modified spectrophotometric assay for porphobilinogen deaminase: its application in the detection of both carriers and patients with acute intermittent porphyria.

Authors:  J Vázquez-Prado; F J Sánchez-Anzaldo; G J Ruiz-Argüelles; E Marín-López; E Lobato-Mendizábal
Journal:  J Inherit Metab Dis       Date:  1995       Impact factor: 4.982

4.  Acute intermittent porphyria in Finland: 19 mutations in the porphobilinogen deaminase gene.

Authors:  R Kauppinen; S Mustajoki; H Pihlaja; L Peltonen; P Mustajoki
Journal:  Hum Mol Genet       Date:  1995-02       Impact factor: 6.150

5.  Quantitative analysis of SMN1 gene and estimation of SMN1 deletion carrier frequency in Korean population based on real-time PCR.

Authors:  Tae-Mi Lee; Sang-Wun Kim; Kwang-Soo Lee; Hyun-Seok Jin; Soo Kyung Koo; Inho Jo; Seongman Kang; Sung-Chul Jung
Journal:  J Korean Med Sci       Date:  2004-12       Impact factor: 2.153

6.  Novel HMBS founder mutation and significant intronic polymorphism in Spanish patients with acute intermittent porphyria.

Authors:  E Guillén-Navarro; P Carbonell; G Glover; M Sánchez-Solís; A Fernández-Barreiro
Journal:  Ann Hum Genet       Date:  2004-09       Impact factor: 1.670

7.  Evidence for an ancestral founder of the common R116W mutation in the hydroxymethylbilane synthase gene in acute intermittent porphyria in The Netherlands.

Authors:  F W M de Rooij; F G Kavelaars; H Koole-Lesuis; J H P Wilson
Journal:  Cell Mol Biol (Noisy-le-grand)       Date:  2009-07-01       Impact factor: 1.770

Review 8.  Finishing touches: post-translational modification of protein factors involved in mammalian pre-mRNA 3' end formation.

Authors:  Kevin Ryan; David L V Bauer
Journal:  Int J Biochem Cell Biol       Date:  2008-04-01       Impact factor: 5.085

9.  Ancestral founder of mutation W283X in the porphobilinogen deaminase gene among acute intermittent porphyria patients.

Authors:  Xiaoye Schneider-Yin; Martin Hergersberg; David E Goldgar; Urszula B Rüfenacht; Macé M Schuurmans; Hervé Puy; Jean-Charles Deybach; Elisabeth I Minder
Journal:  Hum Hered       Date:  2002       Impact factor: 0.444

Review 10.  Porphyria in Sweden.

Authors:  S Thunell; Y Floderus; A Henrichson; P Harper
Journal:  Physiol Res       Date:  2006       Impact factor: 1.881

View more
  4 in total

1.  GBA mutations in Gaucher type I Venezuelan patients: ethnic origins and frequencies.

Authors:  Gilberto Gómez; Sergio Arias; Leonor Cárdenas; Dalal Zoghbi; Irene Paradisi
Journal:  J Genet       Date:  2017-09       Impact factor: 1.166

2.  Seven Novel Mutations in Bulgarian Patients with Acute Hepatic Porphyrias (AHP).

Authors:  Sonya Dragneva; Monika Szyszka-Niagolov; Aneta Ivanova; Lyudmila Mateva; Rumiko Izumi; Yoko Aoki; Yoichi Matsubara
Journal:  JIMD Rep       Date:  2014-07-06

3.  Spinocerebellar ataxias in Venezuela: genetic epidemiology and their most likely ethnic descent.

Authors:  Irene Paradisi; Vassiliki Ikonomu; Sergio Arias
Journal:  J Hum Genet       Date:  2015-11-05       Impact factor: 3.172

4.  Acute intermittent porphyria associated with respiratory failure: a multidisciplinary approach.

Authors:  Mayra Gonçalves Menegueti; Alkmim-Teixeira Gil Cezar; Karin Aparecida Casarini; Kátia Simone Muniz Cordeiro; Anibal Basile-Filho; Olindo Assis Martins-Filho; Maria Auxiliadora-Martins
Journal:  Crit Care Res Pract       Date:  2011-05-11
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.